GoldenGolden
Advanced Search
Shionogi

Shionogi

Japan-based pharmaceutical company focused on the manufacturing and distribution of pharmaceuticals.

All edits

Edits on 4 May, 2021
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 4 May, 2021
Edits made to:
Infobox (+3 properties)
Infobox
Industry
Biotechnology
Neelam Jhaveri
Neelam Jhaveri edited on 4 May, 2021
Edits made to:
Timeline (+1 events) (+183 characters)
Timeline

May 3, 2021

Shionogi, Inc appoints Executive Vice President Nathan McCutcheon to the Role of Chief Operating Officer and Senior Vice President Gianine Esposito will join the Executive Committee.
Edits on 19 Apr, 2021
Golden AI
Golden AI edited on 19 Apr, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Invested in
Edits on 12 Jun, 2020
Golden AI"Add alternate names"
Golden AI edited on 12 Jun, 2020
Edits made to:
Infobox (+2 properties)
Infobox
Also known as
しおのぎせいやく
Official name
Shionogi & Co., Ltd.
Edits on 28 May, 2020
Golden AI"Wikidata import from WikidataImport1"
Golden AI edited on 28 May, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Wikidata entity ID
Q3482319
Edits on 16 Mar, 2020
Arthur Smalley
Arthur Smalley edited on 16 Mar, 2020
Edits made to:
Article (-5 characters)
Article

After the outbreak of Covid-19 in early 2020, clinical trials have begun to determine the suitability of Shionogi drugs for the treatment of coronavirus. Various combinations of Shinogi and Toyama Chemical drugs baloxavir marboxil/favipiravir and lopinavir/ritonavir are involved in 2 trials. Baloxavir marboxil is a Cap-dependent endonuclease inhibitor and favipiravir is a guanine analog RNA-dependent RNA polymerase inhibitor approved for influenza.

Edits on 13 Mar, 2020
Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+5/-5 characters)
Article

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong Kong, United Kingdom, ChinaChina, and Singapore.

Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+9/-9 characters)
Article

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong KongHong Kong, United Kingdom, China, and Singapore.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+18/-18 characters)
Article

After the outbreak of Covid-19 in early 2020, clinical trials have begun to determine the suitability of Shionogi drugs for the treatment of coronavirus. Various combinations of Shinogi and Toyama Chemical drugs baloxavir marboxil/favipiravir and lopinavir/ritonavir are involved in 2 trials. Baloxavir marboxilBaloxavir marboxil is a Cap-dependent endonuclease inhibitor and favipiravir is a guanine analog RNA-dependent RNA polymerase inhibitor approved for influenza.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+10/-10 characters)
Article

In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in Atlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New JerseyNew Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+7/-7 characters)
Article

In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in AtlantaAtlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+5/-5 characters)
Article

Shionogi traces it's history back to 1878 when Gisaburo Shiono, Sr., founder of the Company, launched Shiono Gisaburo Shoten a drug wholesaler at the present site of the head office in Doshomachi, OsakaOsaka. In 1919, Shiono Gisaburo Shoten and Shiono Seiyakusho merged, and the newly formed company was named Shionogi Shoten. The name was later changed to Shionogi & Co., Ltd.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+5/-5 characters)
Article

Shionogi group is made up of 11 companies based in JapanJapan and 6 more based in Taiwan, USA, Hong Kong, United Kingdom, China, and Singapore.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+9/-9 characters)
Article

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong Kong, United Kingdom, China, and SingaporeSingapore.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+3/-3 characters)
Article

After the outbreak of Covid-19 in early 2020, clinical trials have begun to determine the suitability of Shionogi drugs for the treatment of coronavirus. Various combinations of Shinogi and Toyama Chemical drugs baloxavir marboxil/favipiravir and lopinavir/ritonavir are involved in 2 trials. Baloxavir marboxil is a Cap-dependent endonuclease inhibitor and favipiravir is a guanine analog RNA-dependent RNARNA polymerase inhibitor approved for influenza.

Arthur Smalley
Arthur Smalley approved a suggestion from Golden's AI on 13 Mar, 2020
Edits made to:
Article (+14/-14 characters)
Article

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong Kong, United KingdomUnited Kingdom, China, and Singapore.

Arthur Smalley
Arthur Smalley edited on 13 Mar, 2020
Edits made to:
Article (+1 characters)
Article

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, purchase, manufacture, and sale of pharmaceuticals, as well as pharmaceutical-related businesses. Shionogi's research scientists have discovered therapeutics including naldemedine, rosuvastatin and dolutegravir, and are currently working on many more potential future products. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Arthur Smalley
Arthur Smalley edited on 13 Mar, 2020
Edits made to:
Description (+100 characters)
Article (+1822 characters)
Topic thumbnail

Shionogi

Japan-based pharmaceutical company focused on the manufacturing and distribution of pharmaceuticals.

Article

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. Shionogi's research scientists have discovered therapeutics including naldemedine, rosuvastatin and dolutegravir, and are currently working on many more potential future products. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi traces it's history back to 1878 when Gisaburo Shiono, Sr., founder of the Company, launched Shiono Gisaburo Shoten a drug wholesaler at the present site of the head office in Doshomachi, Osaka. In 1919, Shiono Gisaburo Shoten and Shiono Seiyakusho merged, and the newly formed company was named Shionogi Shoten. The name was later changed to Shionogi & Co., Ltd.

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong Kong, United Kingdom, China, and Singapore.

In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in Atlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients.

...
Covid-19 Treatment

After the outbreak of Covid-19 in early 2020, clinical trials have begun to determine the suitability of Shionogi drugs for the treatment of coronavirus. Various combinations of Shinogi and Toyama Chemical drugs baloxavir marboxil/favipiravir and lopinavir/ritonavir are involved in 2 trials. Baloxavir marboxil is a Cap-dependent endonuclease inhibitor and favipiravir is a guanine analog RNA-dependent RNA polymerase inhibitor approved for influenza.

Arthur Smalley
Arthur Smalley edited on 13 Mar, 2020
Edits made to:
Infobox (-1 properties)
Golden AI
Golden AI edited on 13 Mar, 2020
Edits made to:
Infobox (+1 properties)
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.